Basaglar and Orkambi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Basaglar (insulin glargine) and Orkambi (ivacaftor; lumacaftor). Common drug interactions include drug ineffective among females and cystic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Basaglar and Orkambi. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Basaglar?

Basaglar has active ingredients of insulin glargine. eHealthMe is studying from 19,807 Basaglar users. Check the latest studies of Basaglar.

What is Orkambi?

Orkambi has active ingredients of ivacaftor; lumacaftor. eHealthMe is studying from 9,496 Orkambi users. Check the latest studies of Orkambi.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 05, 2026

18 people who take Basaglar and Orkambi together, and have interactions are studied.

What are the common drug interactions of Basaglar and Orkambi, by gender? *:

female:

Drug ineffective
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Hospitalisation
Infection

male:

Cystic fibrosis (disease of the secretary glands)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Vomiting
Withdrawal syndrome (a discontinuation syndrome is a set of symptoms occurred due to discontinuation of substance)
Pyrexia (fever)
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Hepatomegaly (abnormal enlargement of the liver)
Hospitalisation
Pulmonary function test decreased

What are the common drug interactions of Basaglar and Orkambi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Cystic fibrosis (disease of the secretary glands)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)

20-29:

Pyrexia (fever)

30-39:

Drug ineffective
Pulmonary function test decreased

40-49:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Respiratory tract irritation
Withdrawal syndrome (a discontinuation syndrome is a set of symptoms occurred due to discontinuation of substance)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 18 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Basaglar and Orkambi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously